Dr. Efren C. Manjarrez, MD

Dr. Manjarrez practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Manjarrez's NPI, 1861422917, was assigned on July 4, 2006. Dr. Manjarrez graduated from UC San Diego School of Medicine in 1995. Dr. Manjarrez holds Florida license ME75012.

Dr. Manjarrez's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Manjarrez's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Manjarrez to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Manjarrez practices, 2 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Manjarrez's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dr. Manjarrez is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Manjarrez's licenses on file in 2 states: Florida and California.

Dmand AI lists acute stomach ulcer, chest pain, circulation problems, circulatory problems in extremities, gastrointestinal obstruction, kidney failure, liver disease and pneumonia and respiratory infection among the conditions Dr. Manjarrez treats.

CMS data shows 207 Medicare services from Dr. Manjarrez across 3 procedure codes in 2024, for 89 Medicare patients. Medicare paid $16,517 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 89 Medicare patients who saw Dr. Manjarrez in 2024. The largest group is 75 to 84, with 33 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 55% are also on Medicaid. Their average risk score is 3.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Manjarrez's median patient age at 72, with 52% women.

In 2024, Dr. Manjarrez wrote 339 Medicare Part D claims for 107 patients. 83% of them were for generic drugs. CMS names the drug for 81 of them, across 5 drugs with 11 or more claims each, at $607 in total drug cost. In 2023, CMS named 164 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Manjarrez for performance year 2024, reported as part of a group. Dr. Manjarrez accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Manjarrez, published from 2015 to 2023. 2015 was the busiest year, with 2. The most frequent topics are Aftercare, COVID-19 and Hospitalists. Dr. Manjarrez has published most often in J Gen Intern Med. Dr. Manjarrez's most frequent co-authors are Andrew D. Auerbach, MD, Maralyssa Angelique Bann, MD and Ximena A. Morales, MD.

CMS Open Payments shows 25 general payments to Dr. Manjarrez from 8 drug and device companies from 2016 to 2017. Food and beverage make up the largest share, 100% of the total. Valeant Pharmaceuticals International paid the most, $173.

Dmand AI lists 1 award for Dr. Manjarrez, most recently CMS Stage 1 EHR in 2014.

Dr. Manjarrez graduated from UC San Diego School of Medicine in 1995. Dr. Manjarrez is a member of ACP and SHM.

Dr. Manjarrez is in network with 8 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.